Black Swan Sale

50% Off Elite

Register Now!

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Last Close
Nov 28  •  03:26PM ET
0.2740
Dollar change
+0.0019
Percentage change
0.70
%
Index- P/E- EPS (ttm)-0.48 Insider Own24.66% Shs Outstand48.26M Perf Week-15.59%
Market Cap19.14M Forward P/E- EPS next Y-0.39 Insider Trans0.00% Shs Float- Perf Month-29.45%
Enterprise Value21.38M PEG- EPS next Q-0.10 Inst Own10.48% Short Float- Perf Quarter-53.57%
Income-18.50M P/S- EPS this Y-42.16% Inst Trans-1.98% Short Ratio1.37 Perf Half Y-62.44%
Sales0.00M P/B105.79 EPS next Y20.00% ROA-192.59% Short Interest1.41M Perf YTD-86.30%
Book/sh0.00 P/C3.93 EPS next 5Y-9.52% ROE-1292.87% 52W High2.79 -90.18% Perf Year-90.39%
Cash/sh0.07 P/FCF- EPS past 3/5Y-91.03% - ROIC-914.99% 52W Low0.24 14.17% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility11.71% 12.04% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM18.47% Oper. Margin- ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.78 Sales Y/Y TTM- Profit Margin- RSI (14)34.93 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.78 EPS Q/Q-800.67% SMA20-17.56% Beta-0.51 Target Price8.00
Payout- Debt/Eq59.25 Sales Q/Q- SMA50-34.91% Rel Volume0.98 Prev Close0.27
Employees13 LT Debt/Eq15.83 EarningsOct 31 AMC SMA200-62.51% Avg Volume1.03M Price0.27
IPOJan 31, 2024 Option/ShortNo / Yes EPS/Sales Surpr.-8.33% - Trades Volume1,008,954 Change0.70%
Date Action Analyst Rating Change Price Target Change
Dec-12-24Initiated Rodman & Renshaw Buy $12
Oct-30-24Initiated H.C. Wainwright Buy $12
Sep-24-24Initiated Maxim Group Buy $12
Nov-26-25 08:30AM
Nov-25-25 04:05PM
Nov-24-25 09:00AM
Nov-20-25 08:00AM
Nov-19-25 07:03PM
08:36AM Loading…
08:36AM
Oct-31-25 04:30PM
Oct-24-25 08:30AM
Oct-14-25 08:30AM
Sep-23-25 08:30AM
Sep-12-25 08:30AM
Sep-11-25 08:30AM
Sep-10-25 08:30AM
Aug-27-25 08:30AM
Jul-31-25 04:30PM
08:30AM Loading…
Jul-28-25 08:30AM
Jul-11-25 08:30AM
Jul-09-25 08:30AM
Jul-07-25 04:35PM
Jun-16-25 04:35PM
09:50AM
Jun-09-25 08:30AM
May-16-25 08:30AM
May-14-25 04:30PM
Apr-29-25 09:15AM
09:15AM
Apr-11-25 08:30AM
Apr-08-25 08:30AM
Apr-02-25 08:30AM
Mar-31-25 04:25PM
08:30AM Loading…
Mar-27-25 08:30AM
Mar-21-25 08:30AM
Mar-14-25 08:35AM
Mar-12-25 01:12PM
Mar-04-25 08:30AM
Feb-27-25 08:30AM
Feb-05-25 09:15AM
Dec-30-24 04:30PM
02:12PM
Dec-23-24 07:55AM
Nov-19-24 09:15AM
Nov-14-24 09:15AM
Nov-12-24 04:20PM
Oct-29-24 09:15AM
Oct-28-24 09:31AM
Oct-21-24 07:45AM
Oct-18-24 08:30AM
Oct-16-24 09:15AM
Oct-11-24 09:31AM
Sep-30-24 09:31AM
Sep-19-24 09:31AM
Sep-12-24 09:31AM
Sep-06-24 09:31AM
Aug-20-24 09:31AM
Aug-07-24 06:52PM
Jul-15-24 09:31AM
Jun-25-24 09:31AM
Jun-13-24 09:31AM
Jun-06-24 09:31AM
May-15-24 04:30PM
09:54AM
May-14-24 05:24PM
May-07-24 09:31AM
Apr-25-24 08:00AM
Apr-11-24 09:31AM
Apr-04-24 09:31AM
Mar-28-24 09:31AM
Mar-19-24 09:31AM
Mar-13-24 09:31AM
Mar-06-24 09:31AM
Feb-29-24 05:44PM
Feb-20-24 09:31AM
Feb-13-24 09:31AM
Feb-08-24 09:31AM
Feb-06-24 09:31AM
Jan-31-24 10:00AM
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Khoja HamidChief Scientific OfficerMay 27 '25Buy0.8420,00016,80031,250May 27 05:56 PM